Compare Match Group Inc (MTCH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Novartis AG — how do they compare? Match Group Inc trades at $36.82 (market cap $8.43B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 35.4× Match Group Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| MTCH | NVS | |
|---|---|---|
Market Cap | $8.43B | $298.18B |
Sector | Media | Health |
52-Week High | $41.24 | $168.62 |
52-Week Low | $28.90 | $119.31 |
Enterprise Value | $11.40B | $339.50B |
Dividend Yield | 2.18% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $37.26, up 1.78% on the day, with a bearish technical signal and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 EPS estimates but missing on revenue, as Tinder faces headwinds while Hinge grows. Strong profitability is evident with a 74.8% gross margin and 20.17% net income margin, though high debt levels remain a concern. Recent news highlights institutional buying interest amid ongoing business transformation.
The outlook is cautiously optimistic, supported by a consensus price target of $42.33 (13.6% upside) and no sell ratings. Key opportunities include Hinge's international expansion and Tinder's turnaround potential, but risks involve execution challenges, competitive pressures, and significant leverage. Earnings growth remains the primary catalyst for valuation re-rating.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
